Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKLB1028 in Relapsed or Refractory Acute Myeloid Leukemia
NCT02859948Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Incidence of dose limiting toxicity (DLT) and Adverse Event (AE) at 28 Days. Status: unknown.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02859948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859948.